Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology

Joseph C. Alvarnas, Patrick A. Brown, Patricia Aoun, Karen Kuhn Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan Cassaday, Januario E. Castro, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. De Angelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. KlisovicGary Kupfer, Mark Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina Gregory, Courtney Smith

Research output: Contribution to journalReview article

49 Scopus citations

Abstract

Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org.

Original languageEnglish (US)
Pages (from-to)1240-1279
Number of pages40
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2015

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology'. Together they form a unique fingerprint.

  • Cite this

    Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Barta, S. K., Borate, U., Boyer, M. W., Burke, P. W., Cassaday, R., Castro, J. E., Coccia, P. F., Coutre, S. E., Damon, L. E., De Angelo, D. J., Douer, D., Frankfurt, O., Greer, J. P., Johnson, R. A., Kantarjian, H. M., ... Smith, C. (2015). Acute lymphoblastic leukemia, version 2.2015: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 13(10), 1240-1279. https://doi.org/10.6004/jnccn.2015.0153